On the stock market since 2021, it operates in the world of money and finance. It has 830 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 15% a year on average.
Sales run at $255.6M a year. A small number, but proof the product has real buyers.
It pays out $0.04 per share each year — regular cash for whoever holds the stock.
A loss of $221.0M against $255.6M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 26 sells against just 6 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, HMPT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HMPT is a high-risk stock — not yet profitable, and its future rides on its product catching on.